Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival.
暂无分享,去创建一个
Howard Y. Chang | Jordon K. Wang | B. Freeman | M. Rabinovitch | H. Sawada | Lingli Wang | Molong Li | T. Alastalo | M. Koskenvuo | V. D. Perez | David Pham | Tero‐Pekka Alastalo
[1] T. Quertermous,et al. Disruption of the Apelin-APJ System Worsens Hypoxia-Induced Pulmonary Hypertension , 2011, Arteriosclerosis, thrombosis, and vascular biology.
[2] E. Ashley,et al. BMP promotes motility and represses growth of smooth muscle cells by activation of tandem Wnt pathways , 2011, The Journal of cell biology.
[3] D. Hay,et al. Adrenomedullin and calcitonin gene-related peptide receptors in endocrine-related cancers: opportunities and challenges. , 2010, Endocrine-related cancer.
[4] Y. E. Chen,et al. Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions. , 2010, The Journal of biological chemistry.
[5] G. Hansmann,et al. Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF receptor-beta-dependent pulmonary arterial muscularization. , 2009, American journal of physiology. Lung cellular and molecular physiology.
[6] Ahmad Y. Sheikh,et al. Endogenous regulation of cardiovascular function by apelin-APJ. , 2009, American journal of physiology. Heart and circulatory physiology.
[7] A. Schmidt,et al. S100A4 and Bone Morphogenetic Protein-2 Codependently Induce Vascular Smooth Muscle Cell Migration via Phospho–Extracellular Signal-Regulated Kinase and Chloride Intracellular Channel 4 , 2009, Circulation research.
[8] L. David,et al. Emerging role of bone morphogenetic proteins in angiogenesis. , 2009, Cytokine & growth factor reviews.
[9] A. Leite-Moreira,et al. Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension. , 2009, American Journal of Physiology. Heart and Circulatory Physiology.
[10] J. Axelrod,et al. Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt–β-catenin and Wnt–RhoA–Rac1 pathways , 2009, Journal of Cell Biology.
[11] Y. Tano,et al. Retardation of Retinal Vascular Development in Apelin-Deficient Mice , 2008, Arteriosclerosis, thrombosis, and vascular biology.
[12] Ahmad Y. Sheikh,et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. , 2008, The Journal of clinical investigation.
[13] J. Michaelson. Thiazolidinedione associated volume overload and pulmonary hypertension , 2008, Therapeutic advances in cardiovascular disease.
[14] H. Beppu,et al. Genetic Ablation of the Bmpr2 Gene in Pulmonary Endothelium Is Sufficient to Predispose to Pulmonary Arterial Hypertension , 2008, Circulation.
[15] Y. E. Chen,et al. Molecular recognition of nitrated fatty acids by PPARγ , 2008, Nature Structural &Molecular Biology.
[16] B. Freeman,et al. Nitro-fatty Acid Formation and Signaling* , 2008, Journal of Biological Chemistry.
[17] G. Hansmann,et al. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. , 2008, The Journal of clinical investigation.
[18] A. Fukamizu,et al. Requirement of apelin-apelin receptor system for oxidative stress-linked atherosclerosis. , 2007, The American journal of pathology.
[19] S. Erzurum,et al. Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. , 2007, American journal of physiology. Lung cellular and molecular physiology.
[20] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.
[21] David M. Goldenberg,et al. Peroxisome proliferator-activated receptor-&ggr; antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines , 2007 .
[22] L. van den Berghe,et al. Therapeutic potential of interfering with apelin signalling. , 2006, Drug discovery today.
[23] N. Voelkel,et al. Apoptosis of pulmonary microvascular endothelial cells stimulates vascular smooth muscle cell growth. , 2006, American journal of physiology. Lung cellular and molecular physiology.
[24] S. Farmer,et al. Functional Interaction between Peroxisome Proliferator-Activated Receptor γ and β-Catenin , 2006, Molecular and Cellular Biology.
[25] D. Stewart,et al. Microvascular Regeneration in Established Pulmonary Hypertension by Angiogenic Gene Transfer Materials and Methods Cell Isolation and Culture , 2022 .
[26] D. Stewart,et al. Bone Morphogenetic Protein Receptor-2 Signaling Promotes Pulmonary Arterial Endothelial Cell Survival: Implications for Loss-of-Function Mutations in the Pathogenesis of Pulmonary Hypertension , 2006, Circulation research.
[27] J. Rehfeld,et al. Apelin: A new plasma marker of cardiopulmonary disease , 2006, Regulatory Peptides.
[28] B. Geng,et al. Apelin protects myocardial injury induced by isoproterenol in rats , 2006, Regulatory Peptides.
[29] Y. Chen,et al. Fatty Acid Transduction of Nitric Oxide Signaling , 2005, Journal of Biological Chemistry.
[30] Colleen C Nelson,et al. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? , 2005, Endocrine reviews.
[31] Jifeng Zhang,et al. Nitrolinoleic acid: An endogenous peroxisome proliferator-activated receptor γ ligand , 2005 .
[32] S. Pettersson,et al. The Wnt/beta-catenin signaling pathway targets PPARgamma activity in colon cancer cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[33] S. Hinuma,et al. Apelin is a novel angiogenic factor in retinal endothelial cells. , 2004, Biochemical and biophysical research communications.
[34] J. Dyck,et al. Dichloroacetate Prevents and Reverses Pulmonary Hypertension by Inducing Pulmonary Artery Smooth Muscle Cell Apoptosis , 2004, Circulation research.
[35] M. Abe,et al. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. , 2004, The Journal of clinical investigation.
[36] M. Lea,et al. Inhibition of cell proliferation by potential peroxisome proliferator-activated receptor (PPAR) gamma agonists and antagonists. , 2004, Anticancer research.
[37] A. Davenport,et al. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells , 2004, Regulatory Peptides.
[38] R. Trembath,et al. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia , 2003, Journal of medical genetics.
[39] I. Fantozzi,et al. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. , 2003, American journal of physiology. Lung cellular and molecular physiology.
[40] M. Wick,et al. Peroxisome Proliferator-Activated Receptor Gamma (PPAR&ggr;) Expression Is Decreased in Pulmonary Hypertension and Affects Endothelial Cell Growth , 2003, Circulation research.
[41] P. Thistlethwaite,et al. Signaling molecules in nonfamilial pulmonary hypertension. , 2003, The New England journal of medicine.
[42] W. Wahli,et al. A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity. , 2002, Molecular endocrinology.
[43] J. Rysä,et al. Apelin, the Novel Endogenous Ligand of the Orphan Receptor APJ, Regulates Cardiac Contractility , 2002, Circulation research.
[44] T. Willson,et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. , 2002, Biochemistry.
[45] R. Trembath,et al. Primary Pulmonary Hypertension Is Associated With Reduced Pulmonary Vascular Expression of Type II Bone Morphogenetic Protein Receptor , 2002, Circulation.
[46] R. Trembath,et al. Altered Growth Responses of Pulmonary Artery Smooth Muscle Cells From Patients With Primary Pulmonary Hypertension to Transforming Growth Factor-&bgr;1 and Bone Morphogenetic Proteins , 2001, Circulation.
[47] S. Hodge,et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. , 2000, American journal of human genetics.
[48] R. Trembath,et al. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension , 2000, Nature Genetics.
[49] B. O'dowd,et al. Characterization of Apelin, the Ligand for the APJ Receptor , 2000, Journal of neurochemistry.
[50] P. Libby,et al. PPARγ Activation in Human Endothelial Cells Increases Plasminogen Activator Inhibitor Type-1 Expression PPARγ as a Potential Mediator in Vascular Disease , 1999 .
[51] S. Hinuma,et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. , 1998, Biochemical and biophysical research communications.
[52] Ahmad Y. Sheikh,et al. In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure. , 2008, American journal of physiology. Heart and circulatory physiology.
[53] Jifeng Zhang,et al. Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[54] J. Axelrod,et al. Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt –-catenin and Wnt – RhoA – Rac 1 pathways , 2022 .